Addressing Placebo Response, Therapeutic Misconceptions And Expectations
Source: WCG
By Mark Opler, Ph.D., MPH and Gianna Capodilupo, MA
Double-blind, randomized placebo-controlled clinical trials are highly challenging and resource-intensive. Drug-development costs have risen dramatically over time, yet success rates have not improved. In parallel, rates of placebo response across multiple therapeutic areas are at historic highs and progressively increasing. Multiple reviews in different therapeutic areas, including pain, epilepsy, Crohn’s disease, schizophrenia, and others suggest a worsening trend - year over year, the rates of placebo response are going up.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more